For example, detection of the V617F JAK2 mutation is a part of the diagnostic criteria for myeloproliferative neoplasms in the latest version of WHO classification [1], although consensus is not reached about the detection methods and cut-off levels. This evidence concerns the gene JAK2 and myeloproliferative disorder.